U.S. Markets closed

Achillion price target raised to $15 from $10 at JMP Securities

JMP Securities raised its target on Achillion as the firm is impressed by the initial proof of concept data for ACH-3102. The firm thinks Achillion could become a major competitor in the HCV genotype-1 sector, and it reiterates an Outperform rating on the stock.